BioAge Labs, Inc Cash Flow Conversion Efficiency
BioAge Labs, Inc cash flow conversion efficiency. Based on the latest financial reports, BioAge Labs, Inc (BIOA) has a cash flow conversion efficiency ratio of -0.051x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-19.26 Million) by net assets ($374.91 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of BioAge Labs, Inc (2013–2025)
Cash flow conversion efficiency of BioAge Labs, Inc from 2013 to 2025. This chart illustrates how BioAge Labs, Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for BioAge Labs, Inc for real-time trading data and today's change.
BioAge Labs, Inc Cash Flow Conversion Ratio Explained
BioAge Labs, Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
BioAge Labs, Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BioAge Labs, Inc ranked by their cash flow conversion efficiency. Also see BIOA market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Uchi Technologies Bhd
KLSE:7100
|
0.126x |
|
Fujian Yuanxiang New Materials Co. Ltd. A
SHE:301300
|
N/A |
|
Camil Alimentos S.A
SA:CAML3
|
0.102x |
|
Shenzhen Increase Technology Co Ltd Class A
SHE:300713
|
0.071x |
|
Envipco Holding N.V.
AS:ENVI
|
0.047x |
|
Element 29 Resources Inc
V:ECU
|
-0.008x |
|
2Seventy Bio Inc
NASDAQ:TSVT
|
-0.051x |
|
Chongqing Sifang New Material Co. Ltd.
SHG:605122
|
N/A |
Annual Cash Flow Conversion Efficiency for BioAge Labs, Inc (2013–2025)
The table below shows the annual cash flow conversion efficiency of BioAge Labs, Inc from 2013 to 2025. Review financial flexibility index of BioAge Labs, Inc to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $272.05 Million | $-81.63 Million | -0.300x | -88.18% |
| 2024-12-31 | $323.13 Million | $-51.52 Million | -0.159x | -174.00% |
| 2023-12-31 | $-173.40 Million | $-37.36 Million | 0.215x | -32.97% |
| 2022-12-31 | $-112.56 Million | $-36.18 Million | 0.321x | +123.58% |
| 2017-12-31 | $21.85 Million | $-29.79 Million | -1.363x | -75.73% |
| 2016-12-31 | $48.49 Million | $-37.62 Million | -0.776x | -11.68% |
| 2015-12-31 | $46.36 Million | $-32.20 Million | -0.695x | -77.97% |
| 2014-12-31 | $57.53 Million | $-22.45 Million | -0.390x | +7.82% |
| 2013-12-31 | $65.01 Million | $-27.52 Million | -0.423x | -- |
About BioAge Labs, Inc
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhib… Read more